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ABSTRACT
Objective: To determine the distribution of markers of liver function disorders and 
their association with co-existing fluids and electrolytes states in ambulatory HIV 
infected individuals.
Design: A case-control study.
Setting: Jaramogi Oginga Odinga Teaching and Referral Hospital’s Patient Support 
Centre.
Intervention: Biochemical analysis were performed for serum alanine-aminotranferase 
(ALT), aspartate-amino transferase (AST), total protein, albumin, glucose, urea, 
potassium, sodium, chloride, creatinine phosphate, total and direct bilirubin levels 
as well as  CD4 lymphocyte levels.
Results: Serum liver function markers were significantly altered in HIV infected 
individuals compared to uninfected individuals (mean serum aspartate-amino 
transferase (AST); 45.1U/l v/s 36.9U/l; alanine-aminotransferase (ALT), 36.5U/l v/s 
30.7U/l; direct bilirubin, 4.9µmol/l v/s 4.2µmol/l; total bilirubin, 6.2µmol/l v/s 5µmol/l; 
albumin32.8g/l v/s 34.5g/l and protein 64g/l v/s 67.1g/l; p <0.0001). The prevalence of 
pathological levels of serum liver function markers was also higher in HIV-infected 
patients than HIV-negative participants (ALT, 4.4% v/s 0.7%, p=0.001; AST, 24.5% v/s 
6.7%, p<0.0001; direct bilirubin, 43.1% v/s 36.5%, p=0.026; total bilirubin, 2.3% v/s 0%, 
p=0.002; serum albumin, 60.1% v/s 52.2%, p= 0.009 and serum total protein levels, 52.8% 
v/s 36%, p<0.0001). Gender, age and anti-retroviral treatment were not predictors of 
aberrations in levels of liver function markers in HIV infected patients. Marked CD4 
depletion was associated with enhanced deterioration of liver function markers. Liver 
function anomalies did not conduce co-existing electrolyte anomalies as clinically 
altered ALT states only correlated and co-varied with AST states (r = 0.917) ; direct 
biliribun states co-varied with total bilirubin levels (r = 0.958) and serum album states 
correlated with protein levels (r = 0.917) and vice versa. 
Conclusion: Liver function disorders are not infrequent in HIV infected individuals and 
routine review of liver health status is essential in comprehensive care of HIV patients.
 INTRODUCTION
The  popu la t ion  in fec t ed  wi th  Human 
immunodeficiency virus (HIV) has dramatically 
increased ever since it was described (1). Globally 
nearly 40 million live with HIV infection, with the 
greatest burden of disease in low and middle income 
countries (1). Africa has borne the greatest burden of 
HIV infection with 25 million people living with the 
disease yet disproportionately, scant resources have 
been availed for research exploring and elucidating 
HIV infection and its co-morbid conditions (2). In 
Kenya the prevalence of HIV infection remains at 
5.6% (3), with regional disparities. Since inception 
of highly active anti-retroviral treatment (HAART), 
life expectancy has improved among HIV-infected 
persons occasioning new challenges attributed  to co-
morbid conditions, prolonged drugs use and chronic 
ailment with the virus, among other factors (1).
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Besides predominantly infecting the CD4+ lymphocyte 
cells, studies have elucidated HIV infection of non 
haemopoietic cells, including liver cells (3).  HIV 
infection of liver cells such as the primary Kupffer 
cells, differentiated tissue macrophages, sinusoidal 
cells and haepatocytes proceeds by means of several 
mechanisms. Kupffer cells, sinusoidal cells and 
haepatocytes can be infected by the HIV virus in 
vivo (3). As haepatocyte cell lines do not express 
CD4 cell surface markers, it is thought that their 
infection with the HIV virus is non CD4 dependent 
(4). Haepatocytes may act as transient reservoirs of the 
HIV virus, but in some instances undergo apoptosis 
leading to pro-fibrotic activity of stellate haepatic 
cells (5). Liver histology in HIV patients have shown 
a common pattern of portal vein occlusion, peri-portal 
or peri-sinusoidal fibrosis, low grade inflammation 
and steatosis (6).
 Various forms of liver diseases have therefore been 
described among HIV infected patients including non-
alcoholic fatty liver diseases (NAFLD), non-alcoholic 
steatohaepatitis (NASH), haepatocellular cancer 
(HCC) and liver decompensation. Decompensated 
portal hypertension in HIV patients presents 
with manifestations such as ascites and bleeding 
oesophageal varices without cirrhosis at histology 
(7). 
In addition to direct adverse effects of the HIV virus, 
a variety of factors have been identified as being 
associated with damage to liver structure and function 
in HIV patients including: anti-retroviral and non-
anti-retroviral drugs toxicities; tumours (lymphoma 
and Kaposi sarcoma); and opportunistic infections 
such as cytomegalovirus or mycobacterium and co-
infection with Hepatitis B virus (HBV) or Hepatitis 
C virus (HCV) (8).
 Anti-retroviral haepatotoxicity has been 
attributed to nucleoside reverse transcriptase 
inhibitors (NRTIs), protease inhibitors (PIs) and 
non-nucleotide reverse transcriptase (NNRTIs) (9). 
These drugs afflict liver health and function by way of 
hypersensitivity, direct mitochondrial toxicity and /
or disturbance of lipid or sugar metabolism (10). Anti-
retroviral drug-related liver injury has prominently 
been one of the causes of treatment discontinuation 
as well as a variety of negative clinical outcomes 
(11). Consequent discontinuation of anti-retroviral 
drugs (ARVs) on the other hand hinders effective 
and sustained suppression of the HIV virus. As a 
result ARV- haepatotoxicity is a major challenge that 
strains medical budgets due to repeated hospital 
visits or admissions in order to manage the disorders 
resulting from it. There is need to investigate the 
burden, pathogenesis and determinants of liver 
diseases in HIV patients, as a part of comprehensive 
HIV management strategy in every health setting. 
 In a  Swiss cohort of 2365 HIV –infected patients 
not co-infected with HBV or HCV, in whom  levels of 
alanine aminotransferase (ALT) was monitored, 16% 
had chronically elevated levels of ALT (defined as >2x 
upper limit of normal (12). Determinants associated 
with these elevations were HIV RNA, prolonged 
exposure to anti-retroviral treatment (ART), high 
body mass index (BMI), alcohol and increasing age. 
In a study involving a Polish cohort of 182 HIV– 
infected individuals on HAART followed for eight 
years, Anita and colleagues (11) established that the 
most common clinical presentation was asymptomatic 
enzyme elevation, usually <10times the upper limit 
of the normal range. Lucien et al (13) monitored the 
levels of transaminases in HIV patients attending 
Central Hospital Yaounde, Cameroon, involving 150 
participants over a three year period, and established 
that 54% and 24.6% had elevated levels of AST and 
ALT respectively.
 Pathological and epidemiological studies of 
HIV-related liver health and disease have largely been 
done in resource rich, high income countries, yet it 
is projected the burden of HIV infection is high in 
resource scarce developing countries where negligible 
research on liver health in HIV infected individuals 
occurs (14). 
 Common patient screening strategies in long 
term management of HIV patients in Kenya involves 
the use of CD4 levels and on occasion viral load, 
as means of assessing progression of disease and 
treatment. Organ specific screening is a rare approach 
for assessing regular organ function partly explainable 
by the inhibiting cost of involved procedures. 
However studies have persistently reported the 
impact of HIV infection, ARVs and co-morbidities 
on various vital organs as constituting significant 
threats. 
 This study aims at determining distribution of 
liver function markers in HIV patients attending the 
Patients Support Centre (PSC) of Jaramogi Oginga 
Odinga Teaching and Referral Hospital (JOOTRH) 
in Kisumu County, Kenya. It also explored the 
association of liver function markers and the pattern 
of concurrent alteration of other serum electrolytes. 
Liver enzymes AST and ALT, total bilirubin and direct 
bilirubin, protein and albumin levels and states were 
analysed as the markers of liver function. 
 
MATERIALS AND METHODS
Subjects: Between November 2012 and April 2013, a 
case-control study was conducted involving 800 HIV 
sero-positive patients from PSC of JOOTRH and 406 
HIV negative controls, over 18 years, able and willing 
to give verbal or written consent and of both gender. 
Enrolled participants in the control group were 
enlisted from among consenting ministry of health 
staff who in the period of the study were due for and 
underwent routine laboratory profiling at JOOTRH, 
as a pre-condition for vaccination against hepatitis B 
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and C vaccinations. Patients were excluded if they had 
known co-infections or co-morbid conditions such as 
hypertension, diabetes or alcohol abuse or history 
of jaundice. Control participants were excluded if 
they were sero-positive for HIV. Ethical approval 
was provided by the ethical committee of JOOTRH.
Specimen handling: Personnel in the PSC undertook 
routine medical review and care of HIV patient 
enrolled in the department and introduced them 
to study. Volunteers were then informed of consent 
provisions and consenting patients sent to the 
hospital’s laboratory where assigned hospital 
laboratory personnel collected blood samples for 
analysis. Collected blood samples were prepared 
and assayed for the levels of the following analytes; 
total protein, albumin, random sugar, direct bilirubin, 
liver transaminases (alanine amino-transferase and 
aspartate amino-transferase), total bilirubin, sodium, 
potassium, chloride, urea and creatinine.   
 Common attributes recorded for both groups 
included age, gender, random blood sugar, Serum 
kidney and liver function parameters. Additional 
attributes obtained for the HIV infected individuals 
were ARV use and CD4 levels. 
 Serum total protein, albumin, creatinine, glucose, 
urea, total and direct bilirubin, and tranaminases 
were assayed using colorimetric method with wave 
length range of 340-670 nm (Bio systems BTS – 330 
Photometer, Biosystems, SA).  Sodium, potassium and 
chloride were measured using combined photometric-
ion exchange and turbidimetry techniques (Eurolyser, 
Eurolyser diagnostic, and Austria).  HIV status of PSC 
patients were confirmed from the patients’ records 
while for the consenting control participants were 
confirmed by ELISA and Western Blot. CD4 + cell 
levels was also determined ( FACSCalibur instrument, 
Becton Dickinson, San Jose, CA).
 Comparison of means was done using student 
t-test while comparison of proportions was done 
using χ 2 and One –way analysis of variance 
where applicable. Linear correlation was used to 
explore association between quantitative variables 
and regression statistics was used to elucidate co-
variation. SPSS version 21 was used for statistical 
analysis. 
RESULTS
Demographics of the 800 HIV positive and 406 
HIV negative participants and the distribution of 
twelve analytes assayed are provided in table 1 and 
2 respectively. 
Table 1
Charactersitics of participants in the study population
                Percent
HIV Positive HIV negative
Male 41.4 32
Female 58.6 68
Old      (≥50yrs) 15 16.5





Key: CD4+-lymphocyte sub-group bearing CD4 membrane markers; ARV- anti-retroviral drugs
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Table 2
Serum electrolytes distribution by HIV status
HIV status
electrolytes Units HIV Positive HIV Negative
Mean Std Dev. Min. Max. Mean Std Dev. Min Max.
Creatinine  µmol/l 95.2 35.6 11.5 410.57 86.2 20.4 40 173.1
Potassium mmol/l 4.2 0.7 2.8 6.4 4.2 0.7 2.9 6
Sodium mmol/l 138.9 6 127 160 139.1 4.9 130 153
Chloride mmol/l 100.2 3.9 90 139 99 3.2 90 108
Urea mmol/l 4.6 2.1 1.5 36.7 4.1 1.0 1.9 8.8
Protein g/l 64 8.4 40 89 67.1 6.9 42 93
Albumin g/l 32.8 5.8 15.5 47.2 34.5 3.9 22.7 43.3
ALT U/l 36.5 16 11 210 30.7 11.6 11.5 145
AST U/l 45.1 18 11.6 301 36.9 9.6 16.3 104
Total 
Bilirubin
µmol/l 6.2 5.5 1.9 70 5 1.6 2.2 14.1
Direct 
Bilirubin 
µmol/l 4.9 4 1.5 62.8 4.2 1.3 2 10.8
Glucose mmol/l 4.2 0.9 2.1 8.6 4.1 0.9 2 6.7
Key: ALT-  alanine-aminotransferase; AST-  aspartate -aminotransferase
Liver Enzymes: Mean aspartate-aminotransferase 
(±)SD was significantly raised in HIV sero-positive 
individuals than in control group [45.1U/L (±18) 
v/s 36.9U/L(±9.6), p<0.0001) (Table 3). HIV positive 
individuals were also had a higher prevalence 
of pathologically elevated AST level (defined as 
>50U/L) than the HIV negative control (24.5% v/s 
6.7%, x^2=56.9,p<0.0001). HIV infected participants 
similarly presented with elevated serum alanine-
aminotransferase levels and more ALT pathology 
than their HIV negative counterparts (36.5 U/L v/s 
30.7 U/L, p<0.0001; 4.4% v/s 0.7%, χ 2 = 11.7, p=0.001 
respectively). However, mean AST  and ALT level 
in HIV infected males were 46 U/L and 37.6 U/L 
respectively which were not significantly different 
from that of females, 44.4 U/L and 35.8 U/L; p=0.226 
and 0.119 respectively. Equally the proportion with 
deranged AST and ALT levels was not significantly 
different in male compared to female (27.2% v/s 
22.6%, χ2=2.2, p=0.137 and 3% v/s 5.3%, p=0.116 
respectively). However comparison of gender by HIV 
status revealed that male and female in HIV positive 
category had significantly raised mean AST and ALT 
level as well as a higher prevalence of pathologically 
altered AST and ALT activity than their counterparts 
in the HIV negative control group.   At 46 U/L and 
37.6 U/L mean AST and ALT in HIV sero-positive 
males were significantly higher than 37.2 U/L and 
31.9 U/L established in males in the control group 
(p<0.0001 and p=0.001). The prevalence of deranged 
AST and ALT activity (>70U/L) in HIV-infected males 
was 27.2% and 3% which were higher than 8.5% and 
1.5% noted in HIV negative males in the control group.
 In HIV afflicted females mean AST and ALT 
were significantly higher than mean AST and ALT 
values in females in the HIV negative control (44.4 
U/L v/s 36.8 U/L, p<0.0001and 35.8 U/L v/s 30.2 
U/L, p<0.0001). Twenty two point six percent of 
females in the HIV + group had deranged AST level 
(defined as > 50 U/l) which was significantly higher 
than the prevalence of abnormal AST levels in the 
HIV negative control (5.8%, p<0.0001).  Fiv point four 
percent of HIV infected females also had clinically 
elevated ALT levels (> 65U/l) as opposed to 0.4% of 
HIV negative females (p<0.001).
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Table 3 









10.3 <0.0001 56.9 <0.0001
Hiv- 36.9 6.7
Male HIV+ 46 27.2
5.7 <0.0001 19.1 <0.0001
Male HIV- 37.2 8.5
Female HIV+ 44.4 22.6
8.7 <0.0001 35.8 <0.0001
Female HIV– 36.8 5.8
Male HIV+ 46 27.2
Female HIV+ 44.4 1.212 0.226 2.2 0.137
Arv-yes 45.3 24.9
Arv-no 44.3 0.615 0.538 23 0.25 0.616
≥50yrs HIV+ 43.6 24.2
3.6 <0.0001 9.8 0.002
≥50yrs HIV- 37.1 6
<50yrs HIV+ 45.3 24.6
9.6 <0.0001 47.1 <0.0001
<50yrs HIV- 36.9 6.8
≥50yrs  HIV+ 43.6 24.2
0.967 0.334 0.008 0.927
<50yrs  HIV+ 45.3 24.6
ARV yes- using anti-retro viral drugs; ARV no: Not on anti-retro viral treatment
Age difference among HIV infected participants was 
not related with differential outcomes in aberrations 
in AST and ALT levels. Thus in patients over 50 
years old with HIV infection, the mean AST (43.6 
U/L) and ALT (36.1 U/L) were not significantly 
higher than 45.3 U/L and 36.6 U/L recorded in HIV 
infected participants below 50 years. Indeed there 
was no correlation between age and AST level or 
ALT (r=0.018, p=0.613 and r=0.003, p=0.924) and 
virtually no variation in AST   or ALT level could 
be attributed to age change (r2 <0.0001) (Figure 1). 
The rate of occurrence of elevated AST states was 
distributed evenly between the two age categories of 
HIV positive patients (24.2% v/s 24.6%, p=0.927). The 
prevalence of pathological ALT levels was also not 
significantly different between the two age groups. 
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Figure 1
Correlation of age and AST in HIV patients
r = 0.018
Even though changes in CD4 levels were not 
accompanied with similar alteration in liver 
transaminases, extreme CD4 depletion (<200cell/
mm3) was associated with highest mean serum 
AST  (Figure  2) and ALT levels.  Nonetheless the 
prevalence of clinically elevated AST and ALT states 
was not related to changes in CD4 lymphocytes count 
(χ2 =3.3, p=0.342 and χ2 = 1.4, p=0.711 respectively). 
Liver enzyme levels and anomalies in patients using 
ARVs remained virtually unchanged in comparison 
to those not using ARVs (4.4% v/s 4.3% and 24.9% 
v/s 23% respectively). 
Figure 2
Mean serum aspartate-aminotransferase level against CD4 cell count
Key; Very low-CD4 <200; Low-201-500; Moderate-501-800; High->800cells/µl
Correlation of changes in liver enzymes to changes in 
other serum electrolytes: In HIV negative controls, AST 
showed strong correlation to ALT (r=0.721) with 52% 
of variations that occurred in ALT associated with 
variations occurring in AST (r2 =0.520) (Figure 3). 
Such correlation was mirrored by HIV+ patients with 
normal AST levels. In this group, AST levels showed 
a strong correlation with ALT (r=0.701) with 49.2% 
co-variation noticed between ALT and AST.  However 
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HIV positive AST  
elevated (AST>50U/L)
HIV positive AST normal 
(< 50U/L)
AST in HIV negative
activity (>50U/L),  an even stronger correlation was 
exemplified (r=0.784) with a higher proportion (61.3%) 
of ALT changes associated with changes in AST levels 
(r2 =0.613). Conversely HIV+ patients with elevated 
ALT activity (females>65U/L;males>70U/L), also 
showed a strong correlation between ALT and AST 
levels (r = 0.917, p<0.0001) with 84% co-variation noted 
between liver enzymes in this group. Thus strong co-
directional shift in levels of ALT and AST was noted 
where AST was regressed against clinically deranged 
ALT cases or where ALT was regressed against cases 
with elevated AST activity. Where the strength of 
correlation was considerably large, it was noticed 
that shifts in the AST levels that predominantly 
resulted in abnormal levels of AST (>50U/L), were 
accompanied by similar shifts in the proportion of the 
co-variant electrolytes towards abnormal level. Thus, 
elevated AST states were accompanied with a higher 
proportion of abnormal ALT states than normal AST 
states (17.3% v/s 0.2%, χ2 = 104.4, p<0.0001). In the 
HIV negative control AST displayed an additional 
mild correlation with glucose only (r=0.102) and 
only a dismal 1% of their values shared common 
variation trends. Similarly in the HIV positive group 
with normal AST levels chloride was the only other 
electrolyte that was correlated with AST (r=0.084, 
p=0.039), with 3.9% of their values noted to have a 
common variation trend. In contrast AST in the HIV 
positive group with abnormal altered AST levels 
(>50U/L), was further correlated with seven other 
electrolytes namely; creatinine, urea, direct bilirubin, 
total bilirubin, sodium, chloride and albumin 
(Table 4, for r-values).The proportion of alteration 
in these seven electrolytes that portrayed common 
variation trend with AST equally diminished 
proportionately from creatinine to albumin in this 
group. However with regard to the seven electrolytes, 
correlation was not necessarily accompanied with co-
directional shift towards anomalous level. Indeed out 
of the seven electrolytes, only total bilirubin shifted 
significantly towards abnormal levels in relation to 
similar shift of AST levels towards such anomalous 
states (abnormal AST v/s normal AST states = 4.1% 
v/s 1.7%, χ2 =3.96, p=0.047). In the remaining six 
(creatinine, urea, directbilirubin, sodium, chloride 
and albumin) the proportion of abnormal cases 
were fairly evenly distributed between HIV infected 
patients with normal AST levels and abnormal 
AST states. This implies that though correlated to 
changes in AST, changes in these six electrolytes are 
not necessarily precipitated from the same source as 
those that resulted in AST anomalous shift.
Table 4
Correlation of serum AST levels with other serum electrolytes
R p-value r2   r P-value r2 R P-value r2
ALT 0.721 <0.0001 0.520 0.701 <0.0001 0.492 0.784 <0.0001 0.613
Creatinine 0.057 0.254 0.003 0.054 0.189 0.003 0.470 <0.0001 0.221
Chloride 0.021 0.668 <0.0001 0.084 0.039 0.007 0.172 0.016 0.030
Sodium 0.008 0.880 <0.0001 0.031 0.441 0.001 0.222 0.002 0.049
Potassium 0.057 0.250 0.003 0.060 0.141 0.004 0.051 0.474 0.003
Urea 0.039 0.433 0.002 0.028 0.496 0.001 0.304 <0.0001 0.092
Glucose 0.102 0.039 0.010 0.076 0.063 0.006 0.127 0.075 0.016
Total 
bilirubin
0.035 0.484 0.001 0.003 0.950 <0.0001 0.227 0.001 0.051
Direct 
bilirubin
0.064 0.195 0.004 0.001` 0.981 <0.0001 0.268 <0.0001 0.072
Protein 0.050 0.311 0.003 0.008 0.845 <0.0001 0.120 0.094 0.014
Albumin 0.046 0.630 0.002 0.020 0.627 <0.0001 0.156 0.029 0.024
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Figure 3
Correlation of serum AST to serum ALT level
r = 0.847
Bilirubin: Serum total bilirubin and direct bilirubin 
were significantly elevated in HIV positive 
participants than in HIV negative controls (6.2µmol/l 
v/s 5µmol/l, p<0.0001 and 4.9µmol/l v/s 4.2µmol/l, 
p<0.0001 respectively). Consequently it was noted 
that HIV infected participants presented with a higher 
prevalence of deranged total bilirubin (>19µmol/l) 
(2.3% v/s 0%, χ2  = 9.3, p =0.002) and direct bilirubin 
levels (4.2µmol/l) (43.1% v/s 36.5%, χ2 = 4.96, 
p = 0.026). Among the HIV infected patients there 
was no association between gender, age and anti-retro 
viral treatment and changes in serum direct or total 
bilirubin. Even though changes in CD4 levels were 
not accompanied with similar alteration in serum 
bilirubin, extreme CD4 depletion (<200cell/mm3) was 
associated with highest mean serum direct bilirubin 
(Figure 4) and total bilirubin. 
Figure  4 
Mean serum direct bilirubin level against CD4 cell count
Key; Very low-CD4 <200; Low-201-500; Moderate-501-800; High->800cells/µl
In HIV negative controls direct bilirubin was strongly 
correlated with total bilirubin levels (r=0.925) with 
92.5% of variations in levels of either electrolyte 
tied to variation in level of the other. On the other 
hand direct bilirubin showed a weak correlation to 
creatinine (r = 0.103) with only 1.4% of alterations 
in levels of either electrolytes associated with 
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group had a weak correlation with creatinine and 
urea (r=0.116 and r= 0.102 respectively). In HIV 
infected participants with normal direct bilirubin 
levels, correlation was only noted between direct 
bilirubin and total bilirubin (r = 0.752, p<0.0001) 
with 56.5% co-variations existing between them (r2 = 
0.565). However, HIV infected patients with normal 
levels of total bilirubin, a stronger correlation was 
noted between total bilirubin and direct bilirubin 
(r = 0.955, p<0.0001) with 91.3%co-vriation between 
the two electrolytes (r2 = 0.913). In contrast in HIV 
infected participants with clinically elevated direct 
bilirubin states (>4.2µmol/l), four other electrolytes 
showed increased correlation with direct bilirubin 
in addition to its co-variation with total bilirubin 
(r= 0.958). These electrolytes included creatinine (r 
= o.412, p<0.0001), urea (r= 0.362, p<0.0001), AST 
(r= 0.212, p<0.0001) and glucose (r= 0.139, p=0.010). 
On the other hand in HIV infected patients with 
raised total bilirubin (>19µmol/l), correlation existed 
between total bilirubin and direct bilirubin only 
(r=0.875, p<0.0001) with 76.6% co-variation between 
them. Pathological shift in levels of bilirubin (direct 
and total) were also in tandem, with all the patients 
with abnormal levels of total bilirubin also having 
abnormal levels of direct bilirubin while none of the 
patients with normal levels of direct bilirubin had 
abnormal levels of total bilirubin. On the other hand 
the strength of correlation between direct bilirubin 
and creatinine in HIV infected patients with abnormal 
levels of direct bilirubin was a pointer to co-existence 
rather than co-directional shift in magnitude of 
pathological alterations of both. Thus even though 
there was 17% co-variation between direct bilirubin 
and creatinine in HIV patients with abnormal direct 
bilirubin levels, the prevalence of abnormal creatinine 
in them (27.5%) was not significantly different from 
the proportion with abnormal creatinine level in HIV 
infected patients with normal direct bilirubin levels 
(25.1%, P=0.429). Urea levels also portrayed similar 
outcomes with a weak correlation not sufficient to 
engender co-directional pathological shift. 
Total Protein and Albumin: Mean total protein (64g/l) 
and albumin (32.8g/l) in the HIV infected individuals 
declined substantially below those of HIV negative 
controls (67.1g/l., p<0.0001 and 34.5g/l, p<0.001 
respectively). The proportion with deranged protein 
levels (defined as <65g/l or >80g/l) and albumin 
levels (<35g/l or >50g/l), was higher in HIV infected 
patients than their HIV negative counterparts (52.8% 
v/s 36%, χ2 =30.5, p<0.0001 and 60.1% v/s 52.2%, χ2 
= 6.9, p=0.009 respectively). Within the HIV infected 
category, gender and anti-retroviral treatment were 
not associated with differential alterations in levels 
and prevalence of serum protein and albumin 
disorders.  HIV sero-positive patients over 50 years 
and below 50 years had almost equal mean protein 
and albumin levels. However younger patients (<50 
years) tended to have a higher prevalence of serum 
protein and albumin disorders than older patients 
(53.4% v/s 31%, χ 2 = 7.7, p=0.005 and 59.7% v/s 
40.5%, χ 2 = 5.8, p=0.016 respectively). 
CD4 depletion (<200cell/mm3) was associated with 
lowest mean serum total protein and albumin (Figure 
5 and 6).  However at every CD4 level, the proportion 
with clinically deranged protein and albumin level 
was over 50%. 
Figure 5 
Mean serum total protein level against CD4 cell count
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Figure 6 
Mean serum albumin level against CD4 cell count
 
Key; Very low-CD4 <200; Low-201-500; Moderate-501-800; High->800cells/µl
In HIV negative controls, protein levels were 
associated only with albumin levels (r = 0.867). 
In HIV infected participants with normal protein 
levels, protein was associated with albumin levels 
(r = 0.705) while in HIV infected participants with 
normal albumin states, albumin was correlated only 
to protein levels (r = 0.738). However in HIV infected 
patients with deranged albumin states (<35g/l or 
>50g/l), albumin level alterations correlated with 
changes in creatinine (r = 0.130), AST (r = 0.097), 
protein (r = 0.841), total bilirubin (r = 0.171), and 
direct bilirubin (r = 0.161). Thus conditions associated 
with albumin anomalies conduced alterations of 
five other electrolytes. On the other hand in HIV 
infected patients with abnormal protein states 
(<65g/l or >80g/l), alterations in levels of protein 
were correlated only with alterations in creatinine (r 
= 0.108) and albumin (r = 0.872) see Figure 7. In these 
two categories, strong co-directional variation existed 
between protein and albumin accounting for over 70% 
of each other’s alterations while the rest registered less 
than 2% co-variations with either protein or albumin. 
Most of protein anomalies were due to depletion 
states (defined as < 65g/l) with only 18 HIV infected 
patients with protein retention states (defined as > 
80g/l). However all albumin anomalies were due 
to depletion states (defined as < 50g/l). All protein 
retention states were accompanied with albumin 
depletion disorders while 97.6% of protein depletion 
states had concomitant albumin depletion disorders. 
Only 24.5% of patients with normal protein levels had 
albumin depletion disorders.  Protein and albumin 
levels had a common shift towards depletion states. 
27.8% of patients with protein retention disorders 
had creatinine retention disorders while 5.6% had 
creatinine depletion states. Conversely in protein 
depletion disorders, 22% had creatinine retention 
disorders while 1.3% had creatinine depletion 
disorders. In patients with normal protein states, 
17.4% had creatinine retention disorders while 1.9% 
had creatinine retention disorders. The distribution 
of pathological creatinine states between patients 
with various protein states indicates that there was 
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Figure 7
Cotrrelation of albumin to proteins in HIV infection with abnormal protein levels
DISCUSSION
The aim of this study was to determine the distribution 
of liver function markers, possible risk factors to which 
anomalous states of liver function markers can be 
attributed and changes in other electrolytes that are 
influenced by or associated with anomalous changes 
in these liver function markers in HIV patients in 
Kisumu County. The characteristics of distribution 
of liver transaminases (AST/ALT), Bilirubin 
and albumin that were assessed were mean and 
proportions. Their correlation with the distribution of 
anomalies of seven serum electrolytes were assessed 
to detect any likely influence of liver malfunction 
on mechanisms responsible for regulating these 
electrolytes in HIV infection. 
 In the current study mean serum transaminase 
levels were higher in HIV infected individuals than 
in the sero-negative individuals. This concurred 
with findings by Ignatius et al (4) that mean liver 
transaminases’ activity levels were higher in HIV 
patients compared HIV negative. While most studies 
reported that ARV treatment were predictors of 
changes in liver transaminases, this was unexpectedly 
not found to be the case in our study.  However, 
Sulkowski (15) alluded that etiopathogenesis of drug-
induced liver injury, are difficult to assess because of 
the presence of many complicating factors, such as 
drug-drug interactions, the clinical condition of the 
patient, and the haepatic effects of various co-morbid 
diseases.  Indeed gender, age and CD4 levels did not 
also explain the various liver enzyme states observed 
in the current. 
 Liver tranaminase anomalous states were 
predominant in HIV than in HIV negative population. 
Kovari et al (12), reported  elevated liver transaminases 
affected 16% of  HIV patients. The current study on 
the other hand found that 24.6% of HIV infected 
participants had transaminitis of any grade. Among 
the HIV infected patients, ARV use, gender, and age, 
did not explain elevation of transaminases. However 
,Ingiliz et al (16) reported that though several studies 
have observed association between ARV use, co-
infection with hepatitis C (HCV) or hepatitis B virus 
(HBV) as well as alcohol consumption with elevation 
of liver transaminases, in a significant proportion 
of the HIV population the underlying explanation 
remains unknown.  In HIV infected individuals 
abnormal levels of serum alanine –aminotranferase 
established levels of enzyme activity correlated 
only levels of aspartete –amino transferase (r = 
0.784) but not with levels of other concomitantly 
anomalously elevated electrolytes. Therefore, though 
other electrolytes anomalies co-existed with elevated 
liver enzyme states in HIV infection, the later could 
not be explained by underlying determinants of 
transaminitis in this population. Patients with 
depleted immunity (<200) had the more prominent 
states of liver function anomalies compared with 
those with more robust immunity.
 Most studies have explored the distribution of 
bilirubin in HIV infection with greater emphasis on the 
underlying determinants contributing to the various 
states of bilirubin. The current study established that 
average bilirubin levels were elevated in HIV patients 
compared to their counter parts without HIV. It also 
established that the prevalence with anomalous 
levels of direct and total bilirubin was higher in 
the HIV group. Findings that gender, age, ART and 
CD4 levels were not explanatory of these anomalous 
levels in HIV infection, contrasted reports from other 
studies. In clinical trials, significant increases in the 
total bilirubin level (>12.5 times the upper limit of 
normal (UNL) were observed in 22%–47% of patients 
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Mean albumin in HIV patients was lower than that in 
the HIV un-infected group in our study. Similarly HIV 
patients were more likely to have hypoalbuminemia 
than HIV uninfected group. Among the HIV infected 
group, gender and ARV use were not associated with 
abnormal albumin. Younger patients had a higher 
prevalence of hypoalbumin states than older patients. 
In patients with advanced immune depletion albumin 
levels were markedly lower than in patients with 
more robust immunity. Though other anomalies of 
other electrolytes co-existed with HIV with abnormal 
albumin levels these were not attributable to the 
abnormal albumin states per se. This finding concurs 
with Mehta et al (17) who denoted that low albumin 
levels are a consequence of HIV infection and that 
albumin <35 g/liter after HIV sero-conversion is 
associated with faster HIV disease progression and 
increase mortality rates.  
 Mean total protein in HIV patients was lower than 
that in the HIV un-infected group and HIV patients 
were more likely to have hypoproteinemia than HIV 
uninfected group in our study. Younger patients had 
a higher prevalence of hypoprotein states than older 
patients. In patients with advanced immune depletion 
protein levels were markedly lower than those with 
more robust immunity. Protein anomalous states 
correlated with albumin states but not with other 
co-existing anomalous electrolytes levels.
CONCLUSION
Markers of liver function are altered in a significant 
proportion of HIV infected individuals. It was also 
noticed that markers indicative of liver function 
anomalies were considerably prominent in extensive 
immune depletion states . Therefore additional studies 
need to be done to establish underlying determinants 
and the impact that liver malfunction has on prognosis 
of HIV patients in general in our local health set up. 
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